Oral Semaglutide Doses Up to 50 mg Explored for Enhanced Type 2 Diabetes Management

Global health remains significantly impacted by Type 2 Diabetes (T2D), a chronic condition often requiring escalating therapeutic strategies to achieve optimal glycemic control and manage associated comorbidities like obesity. While a range of oral anti-diabetic medications serve as foundational treatments, many patients eventually necessitate more potent interventions, including injectable GLP-1 receptor agonists. Oral semaglutide (Rybelsus®) has revolutionized T2D management by offering the convenience of a tablet formulation for a drug class renowned for its robust effects on glucose homeostasis and weight reduction. However, current approved oral doses (up to 14 mg) may not provide maximal benefits for all individuals, indicating a clinical need for more intensive, yet still oral, treatment options. This study aims to determine if higher oral semaglutide doses can address this unmet need.

This Phase 3 randomized study is designed to compare the efficacy and safety of three higher daily doses of oral semaglutide tablets in participants with Type 2 Diabetes who are currently receiving other oral anti-diabetic medicines. Participants will initiate treatment with a 3 mg starting dose, gradually escalating until they are randomized to a final daily dose of 14 mg, 25 mg, or 50 mg oral semaglutide. The intervention period will extend for 68 weeks, during which participants will take one tablet per day. Primary endpoints for the study include changes in blood sugar control (e.g., HbA1c levels) and body weight. The study protocol explicitly excludes pregnant or breastfeeding women, and regular urine pregnancy tests will be conducted for women of childbearing potential.